Drug Approval | July 26, 2022
Lupin receives approval from U.S. FDA for Azilsartan Medoxomil Tablets
The product will be manufactured at Lupin's facility in Nagpur, India.
The product will be manufactured at Lupin's facility in Nagpur, India.
The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.
Sun Pharma will receive from Cassiopea the exclusive right to develop and commercialize WINLEVI in Japan, Australia, New Zealand, Brazil, Mexico and Russia.
An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
WuXi STA opens a new large scale continuous manufacturing plant
Better serving global partners and advancing healthcare innovation
India imported medical devices worth Rs. 63,200 crore in 2021-22, up 41% from Rs. 44,708 crore in 2020-21
Merck’s first microbiology application and training lab in India
With this, the company can start selling Ibuprofen in the European markets.
Subscribe To Our Newsletter & Stay Updated
